TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from AdAlta Ltd. ( (AU:1AD) ) is now available.
AdAlta Ltd. has announced the quotation of new securities on the Australian Securities Exchange (ASX), including 13,009,463 ordinary fully paid shares and 83,333,334 options expiring in June 2028. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially strengthening its market position and providing opportunities for growth and development in its therapeutic offerings.
The most recent analyst rating on (AU:1AD) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.
More about AdAlta Ltd.
AdAlta Ltd. operates in the biotechnology industry, focusing on the development of innovative therapeutic products. The company is known for its proprietary i-body technology platform, which is utilized to create novel treatments for diseases with unmet medical needs.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.62M
For detailed information about 1AD stock, go to TipRanks’ Stock Analysis page.